Department of Cardiovascular Medicine, Tokeidai Memorial Hospital, 2-3, North-1, East-1, Chuo-ku, Sapporo, Hokkaido, 060-0031, Japan.
Department of Cardiovascular Medicine, Sapporo City General Hospital, 1, Kita-11, Nishi13, Chuo-ku, Sapporo, Hokkaido, 060-8604, Japan.
Cardiovasc Interv Ther. 2024 Jul;39(3):273-283. doi: 10.1007/s12928-024-00997-4. Epub 2024 Apr 18.
One of the major problems associated with bare nitinol stent implantation is stent fracture, particularly in the popliteal artery. The purpose of this study was to determine whether drug coated balloons (DCB), interwoven stents (IWS), or plain old balloon angioplasty (POBA) would be suitable for use in distal femoropopliteal (FP) long lesions when an Eluvia stent was implanted proximal to a lesion. This was a multi-center retrospective study enrolling patients undergoing concomitant use of Eluvia with DCB, IWS or POBA for symptomatic atherosclerotic femoropopliteal disease (lesion length > 15 cm) [Rutherford category 2-6] between January 2018 and September 2021. 79 patients with 89 femoropopliteal lesions were enrolled in this study. The mean lesion length and the percentage of the popliteal artery involvement was 24.3 ± 6.4 cm vs 24.0 ± 9.0 cm vs 26.6 ± 6.2 cm and 65.8% vs 89.4% vs 67.8% for the Eluvia + DCB, Eluvia + IWS, and Eluvia + POBA groups, respectively. The 1-year Kaplan-Meier estimates of primary patency and freedom from major adverse limb events (MALEs) were 53.3% vs 44.1% vs 24.2% and 62.4% vs 51.0% vs 28.1%, respectively. Eluvia + POBA was associated with a lower rate for 1-year primary patency (HR 2.49; 95% confidence interval (CI): 1.28-4.87; p = 0.007 and HR 2.38; 95% CI: 1.13-5.77; p = 0.04). In SFA long lesions with proximal Eluvia implantation, distal implantations of either a DCB or IWS were comparable, as opposed to POBA alone which generated worse results.
裸镍钛合金支架植入后主要存在的问题之一是支架断裂,尤其是在腘动脉。本研究旨在探讨在病变近端植入 Eluvia 支架后,药物涂层球囊(DCB)、编织支架(IWS)或普通球囊血管成形术(POBA)是否适用于治疗远端股腘动脉(FP)长段病变。这是一项多中心回顾性研究,纳入了 2018 年 1 月至 2021 年 9 月期间接受 Eluvia 联合 DCB、IWS 或 POBA 治疗的有症状性股腘动脉粥样硬化性疾病(病变长度>15cm [Rutherford 分类 2-6])患者。共纳入 79 例患者的 89 处股腘动脉病变。Eluvia+DCB、Eluvia+IWS 和 Eluvia+POBA 组的平均病变长度和累及腘动脉百分比分别为 24.3±6.4cm 比 24.0±9.0cm 比 26.6±6.2cm 和 65.8%比 89.4%比 67.8%。Eluvia+DCB、Eluvia+IWS 和 Eluvia+POBA 组的 1 年Kaplan-Meier 估计的一期通畅率和免于主要肢体不良事件(MALEs)率分别为 53.3%比 44.1%比 24.2%和 62.4%比 51.0%比 28.1%。Eluvia+POBA 与 1 年一期通畅率降低相关(HR 2.49;95%置信区间(CI):1.28-4.87;p=0.007 和 HR 2.38;95%CI:1.13-5.77;p=0.04)。在近端植入 Eluvia 的 SFA 长段病变中,DCB 或 IWS 的远端植入效果相当,而单独使用 POBA 的效果较差。